Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839315 · ClinicalTrials.gov registry record · Early Phase 1
COVID-19 Vaccination in Rheumatic Disease Patients
A Early Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 58
- Enrollment target
NCT04839315: Clinical Trial Early Phase 1 study, sponsored by Mayo Clinic.
NCT04839315 is a Early Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 58 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04839315, a Early Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.
Primary Outcome
We aim to examine SARS-Cov2 specific antibody, and autoantibody generation
Interventions
- BIOLOGICAL mRNA COVD19 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-02-15 |
| Est. Completion | 2022-02-09 |
| Phase | Early Phase 1 |
Why NCT04839315 stopped before completion
NCT04839315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which mRNA COVD19 vaccine is the first listed.
NCT04839315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04839315 about?
NCT04839315 is a clinical study titled "COVID-19 Vaccination in Rheumatic Disease Patients". The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.
What is the current status of trial NCT04839315?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 58 participants. The study started on 2021-02-15. Estimated completion is 2022-02-09.
What interventions are being tested in trial NCT04839315?
The interventions under investigation include: mRNA COVD19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04839315?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04839315's enrollment target sits among peer trials
58 441st of 2000 higher than 1,555 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI